

# Tuberculosis profile: Indonesia

Population 2019: 271 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	845 000 (770 000-923 000)	312 (285-341)
HIV-positive TB incidence	19 000 (8 000-35 000)	7 (3-13)
MDR/RR-TB incidence**	24 000 (17 000-32 000)	8.8 (6.2-12)
HIV-negative TB mortality	92 000 (86 000-98 000)	34 (32-36)
HIV-positive TB mortality	4 700 (1 900-8 800)	1.7 (0.71-3.2)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	2.4% (1.8-3.3)
Previously treated cases	13% (9-18)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	67% (61-73)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	11% (10-13)

## TB case notifications, 2019

Total new and relapse	562 049
- % tested with rapid diagnostics at time of diagnosis	27%
- % with known HIV status	51%
- % pulmonary	89%
- % bacteriologically confirmed ^	52%
- % children aged 0-14 years	12%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	37%
- % men	51%
Total cases notified	568 987

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	11 708	4.1%
- on antiretroviral therapy	4 995	43%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	52%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	>100%
Laboratory-confirmed cases - MDR/RR-TB ^^	11 463
Patients started on treatment - MDR/RR-TB ^^	5 531
Laboratory-confirmed cases - XDR-TB ^^	33
Patients started on treatment - XDR-TB ^^	29
MDR/RR-TB cases tested for resistance to any fluoroquinolone	3 369

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	83%	565 980
Previously treated cases, excluding relapse, registered in 2018	74%	4 993
HIV-positive TB cases registered in 2018	72%	10 328
MDR/RR-TB cases started on second-line treatment in 2017	45%	2 997
XDR-TB cases started on second-line treatment in 2017	25%	73

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	12%
---	-----



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 9.4% (8.6-10)

## TB financing

National TB budget, 2020 (US\$ millions)	429
- Funding source, domestic	9.8%
- Funding source, international	16%
- unfunded	74%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)